MedPath

Care China-Diabetes

Terminated
Conditions
Cardiovascular Disease
Diabetes
Registration Number
NCT00938119
Lead Sponsor
Johnson & Johnson Medical, China
Brief Summary

This multicenter, prospective, observational registry will assess efficacy and safety outcomes associated with percutaneous coronary intervention (PCI) with implantation of the CYPHER Selectβ„’+ Sirolimus-eluting Coronary Stents in Chinese diabetic patients with coronary artery disease in routine clinical practice.

Detailed Description

The study objective is to assess the incidences of major adverse cardiovascular events (MACE; defined as a composite of clinically driven target-lesion revascularization, cardiac death, any myocardial infarction, and stent thrombosis) at 12-month follow-up, and of stent thrombosis at 1-day, and 1- and 12-month follow-up. Pre-specified analyses will be performed among patient subpopulations according to level of glycemic control (HbA1c level \< 6.5% or \> 6.5%); reference vessel diameter by quantitative coronary angiography (\< 2.5 mm and \> 2.5 mm); and stented length (8-18 mm; 23-33 mm; and \>33 mm). Quantitative coronary angiographic (QCA) analysis will be performed at the core lab of the China Cardiovascular Research Foundation for all pre- and post-index procedure angiograms and during the 12-month follow-up period for the pre- and post-reintervention procedures in those cases of clinically-driven PCI revascularization. Also, multivariable analyses will be conducted to investigate potential predictors of 12-month MACE rate in routine clinical practice.

The registry will be conducted at about 45 centers in China, where the CYPHER Selectβ„’+ Sirolimus-eluting Coronary Stent is commercially available. Data will be collected on 2,500 diabetic patients treated with the CYPHER Selectβ„’ + Sirolimus-eluting Coronary Stent only.

Primary outcome: MACE (clinically driven TLR, cardiac death, MI, ST) at 12 months Secondary outcome: ARC (probable + definite) ST at 1-day, and 1 and 12 months

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
1603
Inclusion Criteria
  • Patients between the ages of 18 and 80 (inclusive) receiving CYPHER SELECTβ„’+ Sirolimus-eluting Coronary Stent according to standard clinical practice when financially feasible
  • The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
  • Patient has diagnosis of diabetes or is diagnosed with it before or during the index procedure hospitalization based on disease diagnosis criteria
Exclusion Criteria
  • Any contraindication to any of the following medications: aspirin, heparin, thienopyridines (clopidogrel/ticlopidine), stainless steel, contrast agents, or sirolimus
  • An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment
  • Cardiogenic shock
  • Terminal illness with life expectancy <1 year
  • ST-segment elevation myocardial infarction within 7 days prior to the index procedure
  • Any patient who received coronary stent(s) within 1 year

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
MACE (clinically driven TLR, cardiac death, MI, ST) at 12 months12 months
Secondary Outcome Measures
NameTimeMethod
ARC (probable + definite) ST at 1-day, and 1 and 12 months12 months

Trial Locations

Locations (46)

The First Hospital of China Medical University

πŸ‡¨πŸ‡³

Shenyang, Liaoning, China

Xijing Hospital

πŸ‡¨πŸ‡³

Xian, Shanxi, China

Guangdong General Hospital

πŸ‡¨πŸ‡³

Guangzhou, Guangdong, China

Cardiovascular Institute & Fu Wai Hospital

πŸ‡¨πŸ‡³

Beijing, China

Xuan Wu Hospital Capital Medical University

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Peking University, Shenzhen Hospital

πŸ‡¨πŸ‡³

Guangdong, Guangdong, China

The First Affiliated Hospital of Harbin Medical University

πŸ‡¨πŸ‡³

Harbin, Heilongjiang, China

Peking University People's Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

The General Hospital of the People's Liberation Army

πŸ‡¨πŸ‡³

Beijing, Beijing, China

China-Japan Friendship Hospital

πŸ‡¨πŸ‡³

Beijng, Beijing, China

The Second Affiliated Hospital of Jilin University

πŸ‡¨πŸ‡³

Changchun, Jilin, China

The Affiliated Hospital Of Medical College Qingdao University

πŸ‡¨πŸ‡³

Qingdao, Shandong, China

General Hospital of Daqing Oilfield

πŸ‡¨πŸ‡³

Da Qing, China

The Affiliated Hospital of Medical College of Chinese Armed Police Forces

πŸ‡¨πŸ‡³

Tianjin, China

The First Affiliated Hospital of Wenzhou Medical College

πŸ‡¨πŸ‡³

Wenzhou, China

Beijing Anzhen Hospital of the Capital University of Medical Science

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Beijing Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Second Affiliated Hospital of Zhejiang University College of Medicine

πŸ‡¨πŸ‡³

Hangzhou, Zhejiang, China

Lanzhou University First Hospita

πŸ‡¨πŸ‡³

Lanzhou, Gansu, China

Tian Jin Chest Hospital

πŸ‡¨πŸ‡³

Tianjin, Tianjin, China

People's Hospital Of XinJiang Uygur Autonomous Region

πŸ‡¨πŸ‡³

Urumuqi, Xinjiang, China

Sir Run Run Shaw Hospital

πŸ‡¨πŸ‡³

Hang Zhou, China

The First Hospital of Xian Jiao Tong University

πŸ‡¨πŸ‡³

Xi'an, China

NanFang Hospital Affiliated to Southern Medical University

πŸ‡¨πŸ‡³

Guangzhou, Guangdong, China

Peking University Third Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Zhongshan Hospital Xiamen University

πŸ‡¨πŸ‡³

Xiamen, Fujian, China

Shandong Provincial Hospital

πŸ‡¨πŸ‡³

Jinan, China

Shengjing Hospital of China Medical University

πŸ‡¨πŸ‡³

Shen Yang, China

Peking Union Medical College Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

The General Hospital of Shenyang Military Command

πŸ‡¨πŸ‡³

Shenyang, Liaoning, China

Peace Hospital

πŸ‡¨πŸ‡³

ShiJiaZhuang, Hebei, China

Shanxi Cardiovascular Hospital

πŸ‡¨πŸ‡³

Taiyuan, Shanxi, China

The First Hospital of Shanxi Medical University

πŸ‡¨πŸ‡³

Taiyuan, Shanxi, China

General Hospital of Armed Police Forces

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Beijing Chaoyang Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Zhongshan Hospital Fudan University

πŸ‡¨πŸ‡³

Shanghai, Shanghai, China

Shanghai Jiaotong University School of Medicine affiliated Renji Hospital

πŸ‡¨πŸ‡³

Shanghai, Shanghai, China

Henan Provincial People's Hospital

πŸ‡¨πŸ‡³

Zhengzhou, Henan, China

Tianjin First Center Hospital

πŸ‡¨πŸ‡³

Tianjin, Tianjin, China

Shanghai Tenth People's Hospital of Tongji University

πŸ‡¨πŸ‡³

Shanghai, China

Teda International Cardiovascular Hospital

πŸ‡¨πŸ‡³

Tianjin, China

Nanjing First Hospital

πŸ‡¨πŸ‡³

Nanjing, Jiangsu, China

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

πŸ‡¨πŸ‡³

Shanghai, Shanghai, China

The First Affiliated Hospital,Sun Yat-Sen University

πŸ‡¨πŸ‡³

Guangzhou, Guangdong, China

Beijing Tongren Hospital affiliated to Capital Medical University

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Beijing Friendship Hospital

πŸ‡¨πŸ‡³

Beijing, Beijing, China

Β© Copyright 2025. All Rights Reserved by MedPath